Latest news with #EltonJohnAIDSFoundation
Time of India
10 hours ago
- Entertainment
- Time of India
Elton John marks 35 years of sobriety, fans flood social media with support
Sir Elton John has reached a remarkable personal milestone — 35 years of sobriety. The legendary singer-songwriter, now 77, shared a brief but heartfelt note on social media: 'Grateful for all the love on my sobriety birthday.' Tired of too many ads? go ad free now The post quickly drew thousands of messages from fans and fellow artists alike, celebrating his strength and perseverance. 'So proud of you, always,' one user wrote. Another commented, 'You are an inspiration to so many! Congratulations on 35 years sober!' Elton John has spoken openly over the years about his struggles with alcohol, drugs, and bulimia during the height of his fame in the 1970s and '80s. He entered rehab in 1990, a decision he has credited with saving his life. His sobriety has also played a major role in shaping his philanthropic work, including the founding of the Elton John AIDS Foundation. This milestone comes on the heels of his historic 'Farewell Yellow Brick Road' tour, which concluded in 2023 after five years and over 300 shows, making it one of the highest-grossing tours of all time. Despite retiring from touring, Elton remains active in music, film, and advocacy. From addiction and recovery to global stardom and activism, his journey remains one of music's most powerful narratives — and 35 years sober stands as a testament to the legacy he's still building.
New York Post
16-07-2025
- Entertainment
- New York Post
Emma Watson banned from driving for 6 months after speeding
Hermione Danger. Emma Watson was reportedly banned from driving for six months on Wednesday, one year after she got a speeding infraction in Oxford, England. According to the BBC, the 35-year-old 'Harry Potter' star already had had nine points on her license before she drove her blue Audi at 38 mph in a 30 mph zone last July. Advertisement 6 Emma Watson attends the Elton John AIDS Foundation's 31st Annual Academy Awards Viewing Party in March 2023. Getty Images for Elton John AIDS Foundation During Wednesday's five-minute hearing, the High Wycombe Magistrates' Court ordered Watson to pay £1,044 (about $1,400) in fines. The actress reportedly did not attend the hearing. Advertisement The Post has reached out to Watson's rep for comment. 6 Emma Watson seen leaving her hotel in Paris in June 2025. Iammeysam / BACKGRID Watson's lawyer, Mark Haslam, reportedly told the court that she's a student and 'is in a position to pay the fine.' The 'My Week with Marilyn' star has been studying for her master's degree in creative writing at Oxford University since 2023. Advertisement She has not acted since the 2019 Greta Gerwig period film 'Little Women.' In 2023, Watson and her brother Alex launched their own gin brand, Renais. 6 Emma Watson, Daniel Radcliffe, Rupert Grint in 'Harry Potter and the Prisoner of Azkaban.' ©Warner Bros/courtesy Everett Co That same year, she opened up about her decision to take a break from Hollywood. Advertisement 'I wasn't very happy, if I'm being honest,' Watson admitted in an interview with the U.K.'s Financial Times. 'I think I felt a big caged.' 'The thing I found really hard was that I had to go out and sell something that I really didn't have very much control over,' she explained. 'To stand in front of a film and have every journalist be able to say, 'How does this align with your viewpoint?' It was very difficult to have to be the face and the spokesperson for things where I didn't get to be involved in the process.' 6 Emma Watson attends the Soho House Awards in Sept. 2023. Getty Images 6 Emma Watson steps out in Paris on June 8. Aissaoui Nacer / BACKGRID Watson also noted that she was 'held accountable a way that I began to find really frustrating' while she was acting. 'I didn't have a voice, I didn't have a say,' she stated. 'And I started to realise that I only wanted to stand in front of things where if someone was going to give me flak about it, I could say, in a way that didn't make me hate myself, 'Yes, I screwed up, it was my decision, I should have done better.'' 6 Daniel Radcliffe, Emma Watson, Rupert Grint in 'Harry Potter and the Sorcerer's Stone.' ©Warner Bros/Courtesy Everett Collection Advertisement However, the 'Beauty and the Beast' actress promised she will 'absolutely' return to acting one day. 'But I'm happy to sit and wait for the next right thing,' she shared. 'I love what I do. It's finding a way to do it where I don't have to fracture myself into different faces and people. And I just don't want to switch into robot mode anymore.'
Yahoo
14-07-2025
- Health
- Yahoo
WHO endorses Gilead's Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences' newly approved injectable version of lenacapavir to fight HIV, as separate research forecasts a rise in cases in Africa amid foreign aid cuts. Announced at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda, the policy sees injectable lenacapavir – known under the brand name Yeztugo – added to the world's arsenal of tools endorsed by the WHO to curb HIV cases and end the epidemic. Lenacapavir was first approved in 2022 under the brand name Sunlenca for the treatment of HIV infection in adults with multi-drug resistance. An injectable version of lenacapavir given twice a year was approved by the US Food and Drug Administration (FDA) last month, licensed as a pre-exposure prophylaxis (PrEP) option for HIV prevention. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. The Elton John AIDS Foundation commented that the drug 'will fundamentally bend the curve of new HIV infections'. The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. Data reported by Gilead from a Phase III trial showed that Yeztugo led to a 96% reduction in the risk of acquiring HIV. The more accessible dosing will also improve adherence and stigma, meaning more people are likely to take the drug. WHO Director-General Dr Tedros Adhanom Ghebreyesus said: 'While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk. 'The launch of WHO's new guidelines, alongside the FDA's recent approval, marks a critical step forward in expanding access to this powerful tool. WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible.' GlobalData analysts stated that the approval of Yeztugo is a 'momentous step in improving PrEP options available for people vulnerable to contracting HIV'. However, a potential barrier to its global uptake could be cost, with the US list price for Yeztugo sitting at $28,218 per year for each patient. For comparison, GSK's Apretude – the only other injectable PrEP therapy available in the US – costs $22,000 per year, though this is given monthly. The amount of foreign aid that supports Yeztugo's rollout in Africa will therefore impact its availability. Despite scientific breakthroughs such as Yeztugo, the WHO's recommendation comes at a time of concern from public health experts about the impact of foreign aid cuts on HIV cases. Research suggests that cuts in funding made by US President Donald Trump are set to increase transmission rates in Africa. Clinical trial operations, diagnostic testing, and drug availability have already been impacted. The US President's Emergency Plan for AIDS Relief (PEPFAR), which invested significant amounts of money into HIV prevention and treatment last year, has had its funding pulled by the Trump administration. A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse. The WHO itself has been searching for funding recently, after Trump said the US – historically the largest contributor to the organisation – would stop sending money. Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO's overall budget for 2026-2027 will be lower than that for 2024-2025. "WHO endorses Gilead's Yeztugo for HIV prevention" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
14-07-2025
- Health
- Yahoo
WHO endorses Gilead's Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences' newly approved injectable version of lenacapavir to fight HIV, as separate research forecasts a rise in cases in Africa amid foreign aid cuts. Announced at the 13th International AIDS Society Conference (IAS 2025) on HIV Science, in Kigali, Rwanda, the policy sees injectable lenacapavir – known under the brand name Yeztugo – added to the world's arsenal of tools endorsed by the WHO to curb HIV cases and end the epidemic. Lenacapavir was first approved in 2022 under the brand name Sunlenca for the treatment of HIV infection in adults with multi-drug resistance. An injectable version of lenacapavir given twice a year was approved by the US Food and Drug Administration (FDA) last month, licensed as a pre-exposure prophylaxis (PrEP) option for HIV prevention. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. The Elton John AIDS Foundation commented that the drug 'will fundamentally bend the curve of new HIV infections'. The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. Data reported by Gilead from a Phase III trial showed that Yeztugo led to a 96% reduction in the risk of acquiring HIV. The more accessible dosing will also improve adherence and stigma, meaning more people are likely to take the drug. WHO Director-General Dr Tedros Adhanom Ghebreyesus said: 'While an HIV vaccine remains elusive, lenacapavir is the next best thing: a long-acting antiretroviral shown in trials to prevent almost all HIV infections among those at risk. 'The launch of WHO's new guidelines, alongside the FDA's recent approval, marks a critical step forward in expanding access to this powerful tool. WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as possible.' GlobalData analysts stated that the approval of Yeztugo is a 'momentous step in improving PrEP options available for people vulnerable to contracting HIV'. However, a potential barrier to its global uptake could be cost, with the US list price for Yeztugo sitting at $28,218 per year for each patient. For comparison, GSK's Apretude – the only other injectable PrEP therapy available in the US – costs $22,000 per year, though this is given monthly. The amount of foreign aid that supports Yeztugo's rollout in Africa will therefore impact its availability. Despite scientific breakthroughs such as Yeztugo, the WHO's recommendation comes at a time of concern from public health experts about the impact of foreign aid cuts on HIV cases. Research suggests that cuts in funding made by US President Donald Trump are set to increase transmission rates in Africa. Clinical trial operations, diagnostic testing, and drug availability have already been impacted. The US President's Emergency Plan for AIDS Relief (PEPFAR), which invested significant amounts of money into HIV prevention and treatment last year, has had its funding pulled by the Trump administration. A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse. The WHO itself has been searching for funding recently, after Trump said the US – historically the largest contributor to the organisation – would stop sending money. Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO's overall budget for 2026-2027 will be lower than that for 2024-2025. "WHO endorses Gilead's Yeztugo for HIV prevention" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Indianapolis Star
30-06-2025
- Health
- Indianapolis Star
Indiana's Ryan White opened hearts to AIDS fight. Don't abandon his legacy now.
Ryan White was a spirited, bright kid who loved basketball, Nintendo and dreaming big. In 1984, 13-year-old Ryan contracted HIV through a contaminated blood transfusion used to treat his hemophilia. With widespread misconceptions about HIV/AIDS dominating the headlines, and fear overruling facts, Ryan was barred from attending his school and driven from his hometown of Kokomo. His harrowing story suddenly thrust Ryan onto the national stage, where he transformed the attention into a powerful force for changing perceptions about those living with HIV/AIDS. He had no idea how far his message would reach. Yet he was determined to use it for the greater good. His courage inspired the creation of the Elton John AIDS Foundation, which continues to help people across America, and around the world, stay safe and well. At the time of his diagnosis, doctors gave Ryan only six months to live. On April 8, 1990, six precious years later, we sat together at Ryan's bedside and held his hands as he lost his young, heroic life to AIDS. First lady Barbara Bush attended his funeral, and businessman Donald Trump came to the family home to pay his respects. When Americans needed to take compassionate action, Ryan opened the door and urged everyone to take heart and to help. Four months later, in his name, Congress nearly unanimously enacted the Ryan White CARE Act – providing essential HIV care and treatment to Americans living with the virus. After years of fearmongering and paralysis, the U.S. government had finally committed to join the fight against our common enemy: AIDS. Ryan would be grateful for the progress being made. Today, more than 500,000 Americans living with HIV get lifesaving treatment through the Ryan White CARE Act. In 2019, President Trump proudly launched the End the HIV Epidemic initiative in his State of the Union address − a focused prevention effort to end the HIV epidemic in America by 2030. This evidence-based strategic initiative has achieved remarkable results, reducing new HIV infections by 21% in targeted communities and connecting people newly diagnosed with HIV to vital care and support services. This push to end AIDS is in full swing across America, but the work is not done yet – with young people, particularly in the South, now most severely impacted. We are grateful that the draft budget before Congress continues critically important funding for the Ryan White CARE Act and the End the HIV Epidemic efforts. That is an affirmation of these programs' effectiveness and bipartisan support. However, the proposal also would end federal funding to states for HIV surveillance, testing and education; for community-based organizations that reach those most at risk; and for substance abuse treatment and mental health programs that are crucial for driving down HIV infections. Attempts to cut Medicaid are also alarming, as more than 40% of people living with HIV have their care and treatment covered by Medicaid. Without this essential insurance, scores of people living with HIV won't get the care and medicines they need to keep them healthy. The president has said don't mess with Medicaid. We agree. Programs that provide treatment, fuel prevention and fight stigma should be expanded, not eliminated, as we work toward eradicating the disease that ended Ryan's life. The game-changing opportunity of the moment is to scale up prevention medication that keeps people HIV-free. The recent American-led development of PrEP − a pill or shot that prevents the virus from taking hold − is just the tool we need to end AIDS, but only if we make it accessible to those who need it. The economics are compelling: 14,000 people can receive generic PrEP ($30 annually) for the lifetime cost of treating one person with HIV ($420,285) − keeping Americans healthy, HIV-free and productive. The moment of truth is here. As the administration and Congress consider their investment priorities for next year, we urge them to continue joining forces in the fight against AIDS in the United States and worldwide. Together, their investments over time have created this once-in-a-generation opportunity to end AIDS in America by 2030, as called for by President Trump. Together they can seize that opportunity by banking on prevention. Ryan would expect nothing less.
